Absence of nuclear factor κB inhibition by NSAIDs in hepatocytes

Hepatology

Volumn 35, Issue 2, 2002, Pages 341-348

  Callejas, Nuria A ^a   Casado, Marta ^b   Boscá, Lisardo ^a   Martín Sanz, Paloma ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3 FLUOROPHENYL) 5,5 DIMETHYL 4 (4 METHYLSULFONYLPHENYL) 2(5H) FURANONE; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; SALICYLIC ACID;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; DRUG ACTIVITY; DRUG EFFECT; ENZYME INHIBITION; FETUS; GENE EXPRESSION; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0036156738     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.31163     Document Type: Article

References (42)

1. Prostaglandin endoperoxide synthase: Regulation of enzyme expression
2. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2
3. The role of cyclooxygenases in inflammation, cancer, and development
4. Differential regulation of inducible and constitutive prostaglandin endoperoxide synthase in osteoblastic MC3T3-E1 cells
5. Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor-α, and lipopolysaccharide
6. Cyclooxygenase-deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis
7. Aspirin use and reduced risk of fatal colon cancer
8. Cyclooxygenase-independent actions of cyclooxygenase inhibitors
9. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
10. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
11. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing
12. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β
13. Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinase-2 and -9 in fetal rat hepatocytes
14. Tumor invasion and metastasis: An imbalance of positive and negative regulation
15. Extracellular matrix moieties, cytokines, and enzymes: Dynamic effects on immune cell behavior and inflammation
16. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor
17. Glucagon-induced changes in fructose 2,6-bisphosphate and 6-phosphofructo-2-kinase in cultured rat foetal hepatocytes
18. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction
19. Expression of cyclooxygenase-2 in foetal rat hepatocytes stimulated with lipopolysaccharide and pro-inflammatory cytokines
20. Characterization and hormonal regulation of the promoter of the rat prostaglandin endoperoxide synthase 2 gene in granulosa cells. Identification of functional and protein-binding regions
21. Evidence for common mechanisms in the transcriptional control of type II nitric oxide synthase in isolated hepatocytes. Requirement of NF-κB activation after stimulation with bacterial cell wall products and phorbol esters
22. 2 in activated murine macrophages
23. Regulation of cyclooxygenase-2 expression in hepatocytes by CCAAT-enhancer binding proteins
24. Inhibition of prostaglandin synthesis up-regulates cyclooxygenase-2 induced by lipopolysaccharide and peroxisomal proliferators
25. Aspirin induces cell death and caspase-dependent phosphatidylserine externalization in HT-29 human colon adenocarcinoma cells
26. Cyclooxygenases: Structural, cellular, and molecular biology
27. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2
28. Sulindac sulfide alters the expression of cyclin proteins in HT-29 colon adenocarcinoma cells
29. Design of selective inhibitors of cyclooxygenase-2 as nonulcerogenic anti-inflammatory agents
30. The NF-κB and IκB proteins: New discoveries and insights
31. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis
32. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
33. Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines
34. NF-κB and Rel proteins: Evolutionarily conserved mediators of immune responses
35. NF-κB: A lesson in family values
36. Signal-induced degradation of IκBα requires site-specific ubiquitination
37. The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation
38. The IKK complex: An integrator of all signals that activate NF-κB?
39. Inhibition of IκB kinase activity by sodium salicylate in vitro does not reflect its inhibitory mechanism in intact cells
40. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-κB
41. In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663)
42. Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx)